AVXT RESEARCH THREAD Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVXT RESEARCH THREAD

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: chirodoc who wrote ()	3/16/2000 12:38:00 AM
From: chirodoc	of 35

AVAX reports positive interim results in M-Vax study March 15, 2000 07:05 PM Eastern Time KANSAS CITY, Mo., March 15 (Reuters) - AVAX Technologies Inc. AVXT said on Wednesday it received positive interim results from a low-dose Phase 2 study of M-Vax, a therapeutic cancer vaccine for post-surgical, stage III metastatic melanoma made by modifying a patient's own tumor cells with a molecule called a "hapten." The purpose of the ongoing study is to evaluate M-Vax's ability to stimulate an immune response against a patient's own tumor cells utilizing a lower vaccine dose than previously tested. Lowering the vaccine dose reduces the amount of tumor tissue required for manufacturing and thereby expands the number of eligible patients, AVAX said in a news release. Preliminary results from 23 patients demonstrated that 65 percent of them responded favorably to the lower dose, as measured by a delayed type hypersensitivity test (DTH), a skin test that measures a patient's immune response against the patient's own tumor cells. The data obtained from this study to date show the same magnitude of positive immunological responses as seen after higher dose M-Vax treatment in earlier studies, the company said. Results in these earlier studies indicated a strong correlation between positive clinical outcomes and M-Vax's ability to induce an immunological response against a patient's own tumor cells. Follow-up of over 350 patients to date continues to support this correlation

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next